SCHEMBL6946706

SCHEMBL6946706

CCc1cnc(Cc2ccc3c(c2)OCO3)nc1Cl

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 1/20 0.44
HSP90AA1 P07900 2/20 0.44
TRAP1 Q12931 2/20 0.44
LTB4R Q15722 1/20 0.43
HSP90B1 P14625 1/20 0.43
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CYP3A4 P08684 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6942607 0.87 CYP3A4 (0.45) ALDH1A1HSD17B10LTB4RPOLBSMN1; SMN2
SCHEMBL6943670 0.86 SMN1; SMN2 (0.42) ALDH1A1HSD17B10HSP90AA1TRAP1LTB4R
SCHEMBL6942102 0.84 ALDH1A1 (0.46) ALDH1A1HSD17B10LTB4RCYP2D6SLC6A2
SCHEMBL6944624 0.84 SMN1; SMN2 (0.49) ALDH1A1HSD17B10POLBSMN1; SMN2CYP3A4
SCHEMBL6944820 0.84 PDE5A (0.47) ALDH1A1SMN1; SMN2CYP2D6LMNAMAPT
SCHEMBL6947146 0.81 SMN1; SMN2 (0.49) ALDH1A1HSD17B10POLBSMN1; SMN2CYP3A4
SCHEMBL28066233 0.81 ALDH1A1 (0.48) ALDH1A1HSD17B10HSP90AA1LTB4RCYP2D6
SCHEMBL6939968 0.81 ALDH1A1 (0.51) ALDH1A1HSD17B10LTB4RSMN1; SMN2CYP2D6
SCHEMBL6946295 0.77 MAOB (0.50) ALDH1A1POLBKDM4EHTT
SCHEMBL6942688 0.77 SMN1; SMN2 (0.46) ALDH1A1HSD17B10LTB4RSMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 ALDH1A1 573/4885HSD17B10 692/4885HSP90AA1 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.